

Eleanor Barnes

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2806679/eleanor-barnes-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

256
papers

16,858
citations

55
h-index

126
g-index

301
ext. papers

24,681
ext. citations

10.6
avg, IF

6.33
L-index

#	Paper	IF	Citations
256	SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.. <i>Cell</i> , 2022 ,	56.2	154
255	A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.. <i>Cell</i> , 2022 , 185, 916-938.e58	56.2	17
254	Monoclonal antibody BTT1023 targeting vascular adhesion protein 1 for treating primary sclerosing cholangitis: BUTEO single-arm Phase II trial. <i>Efficacy and Mechanism Evaluation</i> , 2022 , 9, 1-54	1.7	
253	SARS-CoV-2-Specific T Cell Responses Are Not Associated with Protection against Reinfection in Hemodialysis Patients.. <i>Journal of the American Society of Nephrology: JASN</i> , 2022 ,	12.7	0
252	Divergent trajectories of antiviral memory after SARS-CoV-2 infection.. <i>Nature Communications</i> , 2022 , 13, 1251	17.4	1
251	A simple, robust flow cytometry-based whole blood assay for investigating sex differential interferon alpha production by plasmacytoid dendritic cells.. <i>Journal of Immunological Methods</i> , 2022 , 504, 113263	2.5	
250	NK cells limit therapeutic vaccine-induced CD8T cell immunity in a PD-L1-dependent manner.. <i>Science Translational Medicine</i> , 2022 , 14, eabi4670	17.5	1
249	Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. 2021 ,		25
248	Abbreviated MRI to screen for HCC in patients with cirrhosis. A step forward but a long road ahead. <i>Journal of Hepatology</i> , 2021 ,	13.4	1
247	T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study. <i>Lancet Microbe, The</i> , 2021 ,	22.2	29
246	Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. <i>Cell</i> , 2021 , 184, 5699-5714.e11	56.2	64
245	SARS-CoV-2 in Pediatric Liver Transplant Recipients: The European Experience. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2021 , 74,	2.8	3
244	Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure. <i>Nature Communications</i> , 2021 , 12, 6105	17.4	3
243	Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection. <i>JHEP Reports</i> , 2021 , 3, 100384	10.3	1
242	SARS-CoV-2 Infections Among Patients With Liver Disease and Liver Transplantation Who Received COVID-19 Vaccination. <i>Hepatology Communications</i> , 2021 ,	6	4
241	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>Lancet, The</i> , 2021 , 396, 1979-1993	40	646
240	SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 156-158	18.8	27

239	COVID-19 and liver disease: mechanistic and clinical perspectives. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 , 18, 348-364	24.2	90
238	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet, The</i> , 2021 , 397, 881-891	40	495
237	A haemagglutination test for rapid detection of antibodies to SARS-CoV-2. <i>Nature Communications</i> , 2021 , 12, 1951	17.4	25
236	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. <i>Nature Communications</i> , 2021 , 12, 2055	17.4	37
235	Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. <i>Cell</i> , 2021 , 184, 2348-2361.e6	56.2	549
234	Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. <i>Cell</i> , 2021 , 184, 2201-2211.e7	56.2	269
233	Antibody evasion by the P.1 strain of SARS-CoV-2. <i>Cell</i> , 2021 , 184, 2939-2954.e9	56.2	281
232	Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 1110-1120	3.4	1
231	High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab267 ¹		3
230	SARS-CoV-2 infection in patients with autoimmune hepatitis. <i>Journal of Hepatology</i> , 2021 , 74, 1335-1343	13.4	40
229	Therapeutic vaccination for treatment of chronic hepatitis B. <i>Clinical and Experimental Immunology</i> , 2021 , 205, 106-118	6.2	8
228	Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study. <i>BMC Infectious Diseases</i> , 2021 , 21, 610	4	1
227	Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 1256-1264	3.4	5
226	The rs738409 G Allele in PNPLA3 Is Associated With a Reduced Risk of COVID-19 Mortality and Hospitalization. <i>Gastroenterology</i> , 2021 , 160, 2599-2601.e2	13.3	3
225	Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients. <i>Journal of Hepatology</i> , 2021 , 75, 226-228	13.4	11
224	Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. <i>Journal of Hepatology</i> , 2021 , 74, 567-577	13.4	151
223	Impact of direct-acting antiviral agents on liver function in patients with chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 168-176	3.4	1
222	Liver cT decreases following direct-acting antiviral therapy in patients with chronic hepatitis C virus. <i>Abdominal Radiology</i> , 2021 , 46, 1947-1957	3	4

221	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , 2021 , 397, 99-111	40	2110
220	Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 493-507	3.4	12
219	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021 , 27, 279-288	50.5	135
218	COVID-19 and liver transplantation: the jury is still out - AuthorsPreply. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 11	18.8	
217	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. <i>Nature Medicine</i> , 2021 , 27, 270-278	50.5	225
216	MAIT cell activation augments adenovirus vector vaccine immunogenicity. <i>Science</i> , 2021 , 371, 521-526	33.3	27
215	Longitudinal Analysis of the Utility of Liver Biochemistry as Prognostic Markers in Hospitalized Patients With Corona Virus Disease 2019. <i>Hepatology Communications</i> , 2021 , 5, 1586-1604	6	1
214	Using host genetics to infer the global spread and evolutionary history of HCV subtype 3a. <i>Virus Evolution</i> , 2021 , 7, veab065	3.7	
213	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. <i>Lancet HIV,the</i> , 2021 , 8, e474-e485	7.8	62
212	Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. <i>Cell</i> , 2021 , 184, 4220-4236.e136	42.36	136
211	Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. <i>Nature Communications</i> , 2021 , 12, 5061	17.4	42
210	Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients. <i>PLoS Pathogens</i> , 2021 , 17, e1009804	7.6	7
209	Specific human cytomegalovirus signature detected in NK cell metabolic changes post vaccination. <i>Npj Vaccines</i> , 2021 , 6, 117	9.5	1
208	Cell-free DNA TAPS provides multimodal information for early cancer detection. <i>Science Advances</i> , 2021 , 7, eabh0534	14.3	1
207	Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease.. <i>Gut</i> , 2021 ,	19.2	0
206	Optimising delivery of therapeutic hepatitis B vaccines to induce resident memory T cells in the liver. <i>Journal of Hepatology</i> , 2020 , 73, S886	13.4	2
205	Real-world retreatment of HCV-infected patients with prior failure to direct acting antiviral therapy using sofosbuvir, velpatasvir and voxilaprevir. <i>Journal of Hepatology</i> , 2020 , 73, S336	13.4	3
204	Correspondence on The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related DiseaseP. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	0

203	Determining risk factors for mortality in liver transplant patients with COVID-19. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 643-644	18.8	65
202	The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam. <i>Trials</i> , 2020 , 21, 413	2.8	2
201	Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia. <i>Journal of Hepatology</i> , 2020 , 73, 794-799	13.4	15
200	Hepatitis C vaccines: how close are we to the promised land? 2020 , 208-215		1
199	Viral vectored hepatitis C virus vaccines generate pan-genotypic T cell responses to conserved subdominant epitopes. <i>Vaccine</i> , 2020 , 38, 5036-5048	4.1	6
198	MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	7
197	Genome-Wide Association Study for Alcohol-Related Cirrhosis Identifies Risk Loci in MARC1 and HNRNPUL1. <i>Gastroenterology</i> , 2020 , 159, 1276-1289.e7	13.3	19
196	IgG4-Related Liver and Biliary Disease 2020 , 163-179		
195	Characterizing Hepatitis C Virus-Specific CD4 T Cells Following Viral-Vectored Vaccination, Directly Acting Antivirals, and Spontaneous Viral Cure. <i>Hepatology</i> , 2020 , 72, 1541-1555	11.2	10
194	Expansion of a Novel Subset of PD1+CXCR5-CD4+ T Peripheral Helper Cells in IgG4-Related Disease. <i>Clinical and Translational Gastroenterology</i> , 2020 , 11, e00111	4.2	4
193	The Design and Development of a Multi-HBV Antigen Encoded in Chimpanzee Adenoviral and Modified Vaccinia Ankara Viral Vectors; A Novel Therapeutic Vaccine Strategy against HBV. <i>Vaccines</i> , 2020 , 8,	5.3	11
192	National Institute for Health Research Health Informatics Collaborative: development of a pipeline to collate electronic clinical data for viral hepatitis research. <i>BMJ Health and Care Informatics</i> , 2020 , 27,	2.6	5
191	Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel. <i>Wellcome Open Research</i> , 2020 , 5, 139	4.8	120
190	Bimodal distribution and set point HBV DNA viral loads in chronic infection: retrospective analysis of cohorts from the UK and South Africa. <i>Wellcome Open Research</i> , 2020 , 5, 113	4.8	4
189	Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanisms. <i>Wellcome Open Research</i> , 2020 , 5, 151	4.8	4
188	SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. <i>Wellcome Open Research</i> , 2020 , 5, 181	4.8	38
187	SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. <i>Wellcome Open Research</i> , 2020 , 5, 181	4.8	60
186	Case Report: Application of hepatitis B virus (HBV) deep sequencing to distinguish between acute and chronic infection. <i>Wellcome Open Research</i> , 2020 , 5, 240	4.8	0

185	Autophagy in T cells from aged donors is maintained by spermidine and correlates with function and vaccine responses. <i>ELife</i> , 2020 , 9,	8.9	17
184	Experience from the first UK inter-regional specialist multidisciplinary meeting in the diagnosis and management of IgG4-related disease. <i>Clinical Medicine</i> , 2020 , 20, e32-e39	1.9	4
183	Bimodal distribution and set point HBV DNA viral loads in chronic infection: retrospective analysis of cohorts from the UK and South Africa. <i>Wellcome Open Research</i> , 2020 , 5, 113	4.8	4
182	High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry. <i>Journal of Hepatology</i> , 2020 , 73, 705-708	13.4	144
181	Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus. <i>Value in Health</i> , 2020 , 23, 180-190	3.3	0
180	A Comprehensive Genomics Solution for HIV Surveillance and Clinical Monitoring in Low-Income Settings. <i>Journal of Clinical Microbiology</i> , 2020 , 58,	9.7	15
179	aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. <i>Journal of Hepatology</i> , 2020 , 73, 1368-1378	13.4	41
178	Evidence of tenofovir resistance in chronic hepatitis B virus (HBV) infection: An observational case series of South African adults. <i>Journal of Clinical Virology</i> , 2020 , 129, 104548	14.5	2
177	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. <i>Lancet, The</i> , 2020 , 396, 467-478	40	1274
176	Technical Validation of a Hepatitis C Virus Whole Genome Sequencing Assay for Detection of Genotype and Antiviral Resistance in the Clinical Pathway. <i>Frontiers in Microbiology</i> , 2020 , 11, 576572	5.7	4
175	Impact of virus subtype and host genotype on large-scale RNA structure formation in the genome of hepatitis C virus. <i>Rna</i> , 2020 , 26, 1541-1556	5.8	6
174	Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood-based fibrosis markers in patients with chronic liver disease. <i>Liver International</i> , 2020 , 40, 3071-3082	7.9	17
173	Optimising T cell (re)boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans. <i>Npj Vaccines</i> , 2020 , 5, 94	9.5	5
172	Broad and strong memory CD4 and CD8 T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. <i>Nature Immunology</i> , 2020 , 21, 1336-1345	19.1	615
171	Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. <i>Lancet Infectious Diseases, The</i> , 2020 , 20, 1390-1400	25.5	212
170	Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 1008-1016	18.8	113
169	The Application of Single-Cell RNA Sequencing in Vaccinology. <i>Journal of Immunology Research</i> , 2020 , 2020, 8624963	4.5	8
168	Use of an Outbred Rat Hepacivirus Challenge Model for Design and Evaluation of Efficacy of Different Immunization Strategies for Hepatitis C Virus. <i>Hepatology</i> , 2020 , 71, 794-807	11.2	11

167	Accurate non-invasive diagnosis and staging of non-alcoholic fatty liver disease using the urinary steroid metabolome. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 1188-1197	6.1	5
166	Divergent chemokine receptor expression and the consequence for human IgG4 B cell responses. <i>European Journal of Immunology</i> , 2020 , 50, 1113-1125	6.1	7
165	Case Report: Application of hepatitis B virus (HBV) deep sequencing to distinguish between acute and chronic infection. <i>Wellcome Open Research</i> , 2020 , 5, 240	4.8	
164	The case for a universal hepatitis C vaccine to achieve hepatitis C elimination. <i>BMC Medicine</i> , 2019 , 17, 175	11.4	9
163	FRI-162-Prime-boost vaccination strategies using chimpanzee-Adeno and MVA viral vectored vaccines encoding multiple HBV antigens (CPmutS) and class II invariant chain molecular adjuvants induces robust T-cell and anti-HBs antibody response in mice. <i>Journal of Hepatology</i> , 2019 , 70, e459-e460	13.4	2
162	Electronic Health Informatics Data To Describe Clearance Dynamics of Hepatitis B Surface Antigen (HBsAg) and e Antigen (HBeAg) in Chronic Hepatitis B Virus Infection. <i>MBio</i> , 2019 , 10,	7.8	19
161	Illumina and Nanopore methods for whole genome sequencing of hepatitis B virus (HBV). <i>Scientific Reports</i> , 2019 , 9, 7081	4.9	41
160	A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus. <i>Value in Health</i> , 2019 , 22, 693-703 ³³		8
159	Interpreting Viral Deep Sequencing Data with GLUE. <i>Viruses</i> , 2019 , 11,	6.2	8
158	Non-invasive assessment of portal hypertension by multi-parametric magnetic resonance imaging of the spleen: A proof of concept study. <i>PLoS ONE</i> , 2019 , 14, e0221066	3.7	19
157	Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir. <i>Gastroenterology</i> , 2019 , 157, 692-704.e9	13.3	19
156	Impact of Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients. <i>Journal of Interferon and Cytokine Research</i> , 2019 , 39, 642-649	3.5	4
155	Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group. <i>Journal of Infection</i> , 2019 , 79, 503-512	18.9	12
154	IgG4-related disease. <i>Medicine</i> , 2019 , 47, 804-807	0.6	
153	Interferon lambda 4 impacts the genetic diversity of hepatitis C virus. <i>ELife</i> , 2019 , 8,	8.9	17
152	Activated T-Follicular Helper 2 Cells Are Associated With Disease Activity in IgG4-Related Sclerosing Cholangitis and Pancreatitis. <i>Clinical and Translational Gastroenterology</i> , 2019 , 10, e00020	4.2	16
151	Approaches, Progress, and Challenges to Hepatitis C Vaccine Development. <i>Gastroenterology</i> , 2019 , 156, 418-430	13.3	95
150	Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 135-184	18.8	216

149	Unique patterns of glycosylation in immunoglobulin subclass G4-related disease and primary sclerosing cholangitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019 , 34, 1878-1886	4	19
148	Clinical Manifestations and Long-term Outcomes of IgG4-Related Kidney and Retroperitoneal Involvement in the United Kingdom IgG4-Related Disease Cohort. <i>Kidney International Reports</i> , 2019 , 4, 48-58	4.1	17
147	Case finding and therapy for chronic viral hepatitis in primary care (HepFREE): a cluster-randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 32-44	18.8	12
146	Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors. <i>Hepatology</i> , 2019 , 69, 1861-1872	11.2	43
145	Induction and Maintenance of CX3CR1-Intermediate Peripheral Memory CD8 T Cells by Persistent Viruses and Vaccines. <i>Cell Reports</i> , 2018 , 23, 768-782	10.6	40
144	NOX1 loss-of-function genetic variants in patients with inflammatory bowel disease. <i>Mucosal Immunology</i> , 2018 , 11, 562-574	9.2	51
143	Impact of Interferon Lambda 4 Genotype on Interferon-Stimulated Gene Expression During Direct-Acting Antiviral Therapy for Hepatitis C. <i>Hepatology</i> , 2018 , 68, 859-871	11.2	15
142	Hepatic iron is the major determinant of serum ferritin in NAFLD patients. <i>Liver International</i> , 2018 , 38, 164-173	7.9	38
141	Interferon- γ induces negative biases in emotional processing in patients with hepatitis C virus infection: a preliminary study. <i>Psychological Medicine</i> , 2018 , 48, 998-1007	6.9	13
140	CD161 Defines a Functionally Distinct Subset of Pro-Inflammatory Natural Killer Cells. <i>Frontiers in Immunology</i> , 2018 , 9, 486	8.4	49
139	Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse. <i>Infection and Drug Resistance</i> , 2018 , 11, 1119-1135	4.2	5
138	Unravelling the fate of functional PD1+ T cells in chronic viral hepatitis. <i>Journal of Clinical Investigation</i> , 2018 , 128, 573-576	15.9	3
137	A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection. <i>Frontiers in Immunology</i> , 2018 , 9, 3175	8.4	19
136	The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes. <i>Vaccine</i> , 2018 , 36, 313-321	4.1	24
135	Hepatitis virus (HCV) diagnosis and access to treatment in a UK cohort. <i>BMC Infectious Diseases</i> , 2018 , 18, 461	4	13
134	Reply to: "Multiparametric magnetic resonance imaging to predict clinical outcomes in patients with chronic liver disease: A cautionary note on a promising technique". <i>Journal of Hepatology</i> , 2017 , 66, 457-458	13.4	1
133	Increases in IgE, Eosinophils, and Mast Cells Can be Used in Diagnosis and to Predict Relapse of IgG4-Related Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1444-1452.e6	6.9	69
132	Phosphodiester content measured in human liver by in vivo P MR spectroscopy at 7 tesla. <i>Magnetic Resonance in Medicine</i> , 2017 , 78, 2095-2105	4.4	17

131	Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus. <i>Nature Genetics</i> , 2017 , 49, 666-673	36.3	81
130	No evidence to support a role for <i>Helicobacter pylori</i> infection and plasminogen binding protein in autoimmune pancreatitis and IgG4-related disease in a UK cohort. <i>Pancreatology</i> , 2017 , 17, 395-402	3.8	16
129	Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. <i>Nature Medicine</i> , 2017 , 23, 579-589	50.5	344
128	Immune phenotype and function of natural killer and T cells in chronic hepatitis C patients who received a single dose of anti-MicroRNA-122, RG-101. <i>Hepatology</i> , 2017 , 66, 57-68	11.2	25
127	Targeted reconstruction of T cell receptor sequence from single cell RNA-seq links CDR3 length to T cell differentiation state. <i>Nucleic Acids Research</i> , 2017 , 45, e148	20.1	61
126	Thoracic involvement in IgG4-related disease in a UK-based patient cohort. <i>Respiratory Medicine</i> , 2017 , 132, 117-121	4.6	19
125	Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing. <i>Antiviral Research</i> , 2017 , 146, 139-145	10.8	10
124	IgG4-related sclerosing cholangitis. <i>Clinical Liver Disease</i> , 2017 , 10, 9-16	2.2	9
123	Immunology taught by rats. <i>Science</i> , 2017 , 357, 129-130	33.3	4
122	Interobserver Variability in Histologic Evaluation of Liver Fibrosis Using Categorical and Quantitative Scores. <i>American Journal of Clinical Pathology</i> , 2017 , 147, 364-369	1.9	31
121	Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity. <i>Liver International</i> , 2017 , 37, 1065-1073	7.9	103
120	Hepatitis B vaccine shortage: another symptom of chronic neglect?. <i>BMJ, The</i> , 2017 , 359, j4686	5.9	2
119	CD161(int)CD8+ T cells: a novel population of highly functional, memory CD8+ T cells enriched within the gut. <i>Mucosal Immunology</i> , 2016 , 9, 401-13	9.2	75
118	Characterization of the Specificity, Functionality, and Durability of Host T-Cell Responses Against the Full-Length Hepatitis E Virus. <i>Hepatology</i> , 2016 , 64, 1934-1950	11.2	28
117	The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design. <i>Gut</i> , 2016 , 65, 112-23	19.2	24
116	Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. <i>Journal of Hepatology</i> , 2016 , 64, 308-315	13.4	127
115	Hepitopes: A live interactive database of HLA class I epitopes in hepatitis B virus. <i>Wellcome Open Research</i> , 2016 , 1, 9	4.8	18
114	Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection. <i>Vaccines</i> , 2016 , 4,	5.3	27

113	Evaluation of Viremia Frequencies of a Novel Human Pegivirus by Using Bioinformatic Screening and PCR. <i>Emerging Infectious Diseases</i> , 2016 , 22, 671-8	10.2	34
112	Immunoglobulin G4(+) B-cell receptor clones distinguish immunoglobulin G 4-related disease from primary sclerosing cholangitis and biliary/pancreatic malignancies. <i>Hepatology</i> , 2016 , 64, 501-7	11.2	69
111	Interferon lambda 4 variant rs12979860 is not associated with RAV NS5A Y93H in hepatitis C virus genotype 3a. <i>Hepatology</i> , 2016 , 64, 1377-8	11.2	4
110	Comparison of Next-Generation Sequencing Technologies for Comprehensive Assessment of Full-Length Hepatitis C Viral Genomes. <i>Journal of Clinical Microbiology</i> , 2016 , 54, 2470-84	9.7	78
109	Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans. <i>Hepatology</i> , 2016 , 63, 1455-70	11.2	32
108	Elevated Serum IgG4 Levels in Diagnosis, Treatment Response, Organ Involvement, and Relapse in a Prospective IgG4-Related Disease UK Cohort. <i>American Journal of Gastroenterology</i> , 2016 , 111, 733-43	0.7	117
107	Therapeutic vaccines in HBV: lessons from HCV. <i>Medical Microbiology and Immunology</i> , 2015 , 204, 79-86	4	16
106	Characterization of Hepatitis C Virus Recombination in Cameroon by Use of Nonspecific Next-Generation Sequencing. <i>Journal of Clinical Microbiology</i> , 2015 , 53, 3155-64	9.7	25
105	Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. <i>Gastroenterology</i> , 2015 , 149, 1462-70	13.3	178
104	Global distribution and prevalence of hepatitis C virus genotypes. <i>Hepatology</i> , 2015 , 61, 77-87	11.2	1062
103	Increased IgG4 responses to multiple food and animal antigens indicate a polyclonal expansion and differentiation of pre-existing B cells in IgG4-related disease. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 944-7	2.4	30
102	Screening and treatment for hepatitis C: a balanced perspective. <i>BMJ, The</i> , 2015 , 350, h644	5.9	1
101	Apparent spontaneous clearance of chronic hepatitis C virus infection in a HIV co-infected patient with decompensated cirrhosis: a case report. <i>Aids</i> , 2015 , 29, 982-5	3.5	2
100	A 63-year-old man with a recurrent right-sided pleural effusion. <i>Thorax</i> , 2015 , 70, 504-7	7.3	11
99	Cross-reactivity of hepatitis C virus specific vaccine-induced T cells at immunodominant epitopes. <i>European Journal of Immunology</i> , 2015 , 45, 309-16	6.1	27
98	An expanded taxonomy of hepatitis C virus genotype 6: Characterization of 22 new full-length viral genomes. <i>Virology</i> , 2015 , 476, 355-363	3.6	18
97	ve-SEQ: Robust, unbiased enrichment for streamlined detection and whole-genome sequencing of HCV and other highly diverse pathogens. <i>F1000Research</i> , 2015 , 4, 1062	3.6	39
96	Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. <i>Journal of Hepatology</i> , 2014 , 60, 69-77	13.4	272

95	Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis. <i>Hepatology</i> , 2014 , 59, 1954-63	11.2	121
94	Treatment of chronic viral hepatitis C in children and adolescents: UK experience. <i>Archives of Disease in Childhood</i> , 2014 , 99, 505-10	2.2	23
93	Type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1675-1683	0.7	162
92	Phenotypic differences between IgG4+ and IgG1+ B cells point to distinct regulation of the IgG4 response. <i>Journal of Allergy and Clinical Immunology</i> , 2014 , 133, 267-70.e1-6	11.5	35
91	Effect of interferon- β on cortical glutamate in patients with hepatitis C: a proton magnetic resonance spectroscopy study. <i>Psychological Medicine</i> , 2014 , 44, 789-95	6.9	19
90	A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. <i>Science Translational Medicine</i> , 2014 , 6, 261ra153	17.5	233
89	Hepatitis E virus infection, Papua New Guinea, Fiji, and Kiribati, 2003-2005. <i>Emerging Infectious Diseases</i> , 2014 , 20, 1057-8	10.2	13
88	The emerging mysteries of IgG4-related disease. <i>Clinical Medicine</i> , 2014 , 14 Suppl 6, s56-60	1.9	3
87	Ever closer to a prophylactic vaccine for HCV. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 1109-24	5.4	44
86	Favourable IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype 3a infection and do not predict a sustained virological response after 24 weeks of therapy. <i>Journal of General Virology</i> , 2013 , 94, 1259-1265	4.9	18
85	Prevention of infection caused by immunosuppressive drugs in gastroenterology. <i>Therapeutic Advances in Chronic Disease</i> , 2013 , 4, 167-85	4.9	57
84	CD8 β Expression Marks Terminally Differentiated Human CD8 $^+$ T Cells Expanded in Chronic Viral Infection. <i>Frontiers in Immunology</i> , 2013 , 4, 223	8.4	14
83	Determining the validity of hospital laboratory reference intervals for healthy young adults participating in early clinical trials of candidate vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2013 , 9, 1741-51	4.4	5
82	British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013. <i>HIV Medicine</i> , 2013 , 14 Suppl 4, 1-71	2.7	27
81	Emergence of a distinct HIV-specific IL-10-producing CD8 $^+$ T-cell subset with immunomodulatory functions during chronic HIV-1 infection. <i>European Journal of Immunology</i> , 2013 , 43, 2875-85	6.1	3
80	Eight novel hepatitis C virus genomes reveal the changing taxonomic structure of genotype 6. <i>Journal of General Virology</i> , 2013 , 94, 76-80	4.9	16
79	A modified RNA-Seq approach for whole genome sequencing of RNA viruses from faecal and blood samples. <i>PLoS ONE</i> , 2013 , 8, e66129	3.7	52
78	Infection frequency of hepatitis C virus and IL28B haplotypes in Papua New Guinea, Fiji, and Kiribati. <i>PLoS ONE</i> , 2013 , 8, e66749	3.7	7

77	Human MAIT and CD8 α T cells develop from a pool of type-17 precommitted CD8 α T cells. <i>Blood</i> , 2012 , 119, 422-33	2.2	202
76	Discovery of novel biomarker candidates for liver fibrosis in hepatitis C patients: a preliminary study. <i>PLoS ONE</i> , 2012 , 7, e39603	3.7	34
75	Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. <i>Science Translational Medicine</i> , 2012 , 4, 115ra1	17.5	310
74	HCV genotype-3a T cell immunity: specificity, function and impact of therapy. <i>Gut</i> , 2012 , 61, 1589-99	19.2	15
73	A rare cause of an ileocaecal mass and lymphadenopathy. <i>Gut</i> , 2012 , 61, 819-20, 917	19.2	2
72	Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. <i>Science Translational Medicine</i> , 2012 , 4, 115ra2	17.5	210
71	CD161(+)CD4(+) T cells are enriched in the liver during chronic hepatitis and associated with co-secretion of IL-22 and IFN- γ . <i>Frontiers in Immunology</i> , 2012 , 3, 346	8.4	25
70	Vaccination for hepatitis C virus: closing in on an evasive target. <i>Expert Review of Vaccines</i> , 2011 , 10, 659-72	5.2	86
69	Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. <i>Hepatology</i> , 2011 , 53, 1446-54	11.2	53
68	Vaccines in clinical trials: infectious disease. <i>Expert Review of Vaccines</i> , 2011 , 10, 555-7	5.2	
67	New approaches for biomarker discovery: the search for liver fibrosis markers in hepatitis C patients. <i>Journal of Proteome Research</i> , 2011 , 10, 2643-50	5.6	17
66	Interferon lambdas: the next cytokine storm. <i>Gut</i> , 2011 , 60, 1284-93	19.2	89
65	Failure to detect xenotropic murine leukemia virus-related virus in blood of individuals at high risk of blood-borne viral infections. <i>Journal of Infectious Diseases</i> , 2010 , 202, 1482-5	7	37
64	Full-Length Characterization of Hepatitis C Virus Subtype 3a Reveals Novel Hypervariable Regions under Positive Selection during Acute Infection. <i>Journal of Virology</i> , 2010 , 84, 1664-1664	6.6	78
63	Analysis of CD161 expression on human CD8 α T cells defines a distinct functional subset with tissue-homing properties. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 3006-11	11.5	269
62	Protective effect of human leukocyte antigen B27 in hepatitis C virus infection requires the presence of a genotype-specific immunodominant CD8 α T-cell epitope. <i>Hepatology</i> , 2010 , 51, 54-62	11.2	42
61	The infective causes of hepatitis and jaundice amongst hospitalised patients in Vientiane, Laos. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2010 , 104, 475-83	2	32
60	Virological footprint of CD4 α T-cell responses during chronic hepatitis C virus infection. <i>Journal of General Virology</i> , 2010 , 91, 1396-406	4.9	25

59	What are the prospects for controlling hepatitis C?. <i>PLoS Medicine</i> , 2009 , 6, e1000096	11.6	6
58	Full-length characterization of hepatitis C virus subtype 3a reveals novel hypervariable regions under positive selection during acute infection. <i>Journal of Virology</i> , 2009 , 83, 11456-66	6.6	23
57	Cellular immune responses during high-dose interferon-alpha induction therapy for hepatitis C virus infection. <i>Journal of Infectious Diseases</i> , 2009 , 199, 819-28	7	39
56	Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. <i>Hepatology</i> , 2009 , 49, 1069-82	11.2	115
55	Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. <i>Hepatology</i> , 2009 , 50, 1017-29	11.2	50
54	Genetic history of hepatitis C virus in East Asia. <i>Journal of Virology</i> , 2009 , 83, 1071-82	6.6	169
53	Monocyte derived dendritic cells retain their functional capacity in patients following infection with hepatitis C virus. <i>Journal of Viral Hepatitis</i> , 2008 , 15, 219-28	3.4	29
52	Acute hepatitis C: clinical aspects, diagnosis, and outcome of acute HCV infection. <i>Current Pharmaceutical Design</i> , 2008 , 14, 1661-5	3.3	12
51	Immune Responses Against the Hepatitis C Virus and the Outcome of Therapy 2008 , 71-86		
50	T-cell responses and previous exposure to hepatitis C virus in indeterminate blood donors. <i>Lancet, The</i> , 2005 , 365, 327-9	4.0	42
49	The surveillance and diagnosis of hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2005 , 17, 491-6	2.2	23
48	A theoretical framework for quantitative analysis of the molecular basis of costimulation. <i>Journal of Immunology</i> , 2005 , 175, 1575-85	5.3	42
47	T-cell responses and previous exposure to hepatitis C virus in indeterminate blood donors. <i>Lancet, The</i> , 2005 , 365, 327-329	4.0	11
46	Pervasive influence of hepatitis C virus on the phenotype of antiviral CD8+ T cells. <i>Journal of Immunology</i> , 2004 , 172, 1744-53	5.3	85
45	Analysis of Driver and Passenger CD8+ T-cell responses against variable viruses. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2004 , 271 Suppl 3, S53-6	4.4	16
44	Impact of alpha interferon and ribavirin on the function of maturing dendritic cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 3382-9	5.9	50
43	Longitudinal mapping of protective CD4+ T cell responses against HCV: analysis of fluctuating dominant and subdominant HLA-DR11 restricted epitopes. <i>Journal of Viral Hepatitis</i> , 2004 , 11, 324-31	3.4	20
42	Ultra-sensitive class I tetramer analysis reveals previously undetectable populations of antiviral CD8+ T cells. <i>European Journal of Immunology</i> , 2004 , 34, 1570-7	6.1	52

41	High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. <i>Gastroenterology</i> , 2004 , 127, 924-36	13.3	257
40	Suppression of Hepatitis C Virus Replication is Maintained Long Term following Haart Therapy, in An Individual with HCV/HIV Co-Infection. <i>Antiviral Therapy</i> , 2004 , 9, 139-142	1.6	9
39	Applications and limitations of blood eosinophilia for the diagnosis of acute cellular rejection in liver transplantation. <i>American Journal of Transplantation</i> , 2003 , 3, 432-8	8.7	38
38	Viral escape and T cell exhaustion in hepatitis C virus infection analysed using Class I peptide tetramers. <i>Immunology Letters</i> , 2003 , 85, 165-71	4.1	45
37	Boosting immunity by antiviral drug therapy: a simple relationship among timing, efficacy, and success. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 1855-60	11.5	51
36	Immunity to hepatitis C virus: stunned but not defeated. <i>Microbes and Infection</i> , 2002 , 4, 57-65	9.3	29
35	Direct current cardioversion during pregnancy should be performed with facilities available for fetal monitoring and emergency caesarean section. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2002 , 109, 1406-7	3.7	60
34	The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. <i>Hepatology</i> , 2002 , 36, 743-54	11.2	112
33	T cell failure in hepatitis C virus infection. <i>Viral Immunology</i> , 2002 , 15, 285-93	1.7	18
32	HCV genotypes--role in pathogenesis of disease and response to therapy. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2000 , 14, 229-40	2.5	27
31	The science, economics, and effectiveness of combination therapy for hepatitis C. <i>Gut</i> , 2000 , 47, 159-61	19.2	3
30	Predictors of a favorable response to alpha interferon therapy for hepatitis C. <i>Clinics in Liver Disease</i> , 1999 , 3, 775-91	4.6	12
29	Long-term efficacy of treatment of chronic hepatitis C with alpha interferon or alpha interferon and ribavirin. <i>Journal of Hepatology</i> , 1999 , 31 Suppl 1, 244-9	13.4	13
28	Impact of the COVID-19 pandemic on routine surveillance for adults with chronic hepatitis B virus (HBV) infection in the UK. <i>Wellcome Open Research</i> , 7 , 51	4.8	
27	Evidence of Tenofovir Resistance in Chronic Hepatitis B Virus (HBV) Infection: An Observational Case Series of South African Adults		1
26	Longitudinal analysis of the utility of liver biochemistry in hospitalised COVID-19 patients as prognostic markers		1
25	Cohort Profile: National Institute for Health Research Health Informatics Collaborative: Hepatitis B Virus (NIHR HIC HBV) Research Dataset		1
24	Illumina and Nanopore methods for whole genome sequencing of hepatitis B virus (HBV)		2

23	Activation of MAIT cells plays a critical role in viral vector vaccine immunogenicity		2
22	National Institute for Health Research Health Informatics Collaborative (NIHR HIC): Development of a Pipeline to Collate Electronic Clinical Data for Viral Hepatitis Research		1
21	Hepatitis B virus resistance to tenofovir: fact or fiction? A synthesis of the evidence to date		2
20	Bimodal distribution and set point HBV DNA viral loads in chronic infection: retrospective analysis of cohorts from the UK and South Africa		2
19	Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel		55
18	Negative regulation of ACE2 by interferons in vivo and its genetic control		3
17	SARS-CoV-2 RNA detected in blood samples from patients with COVID-19 is not associated with infectious virus		10
16	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses		7
15	A comprehensive genomics solution for HIV surveillance and clinical monitoring in a global health setting		3
14	Antibody evasion by the Brazilian P.1 strain of SARS-CoV-2		14
13	In vivo negative regulation of SARS-CoV-2 receptor, ACE2, by interferons and its genetic control. <i>Wellcome Open Research</i> , 6, 47	4.8	0
12	Two doses of SARS-CoV-2 vaccination induce more robust immune responses to emerging SARS-CoV-2 variants of concern than does natural infection.		7
11	Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses		6
10	A blood atlas of COVID-19 defines hallmarks of disease severity and specificity		4
9	FXR inhibition reduces ACE2 expression, SARS-CoV-2 infection and may improve COVID-19 outcome		2
8	Divergent trajectories of antiviral memory after SARS-Cov-2 infection		4
7	T-Cell and Antibody Responses to First BNT162b2 Vaccine Dose in Previously SARS-CoV-2-Infected and Infection-Naive UK Healthcare Workers: A Multicentre, Prospective, Observational Cohort Study. <i>SSRN Electronic Journal</i> ,	1	13
6	Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection. <i>SSRN Electronic Journal</i> ,	1	3

5	Reduced Neutralization of SARS-CoV-2 B.1.1.7 Variant from Naturally Acquired and Vaccine Induced Antibody Immunity. <i>SSRN Electronic Journal</i> ,	1	2
4	Vaccine-induced immunity provides more robust heterotypic immunity than natural infection to emerging SARS-CoV-2 variants of concern.		27
3	Examining the Immunological Effects of COVID-19 Vaccination in Patients with Conditions Potentially Leading to Diminished Immune Response Capacity The OCTAVE Trial. <i>SSRN Electronic Journal</i> ,	1	19
2	T-Cell and Antibody Responses to First BNT162b2 Vaccine Dose in Previously SARS-CoV-2-Infected and Infection-Naive UK Healthcare Workers: A Multicentre, Prospective, Observational Cohort Study. <i>SSRN Electronic Journal</i> ,	1	13
1	Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serum		3